Roivant Sciences Ltd. ROIV
Institutional shares held
443 Million
6.03M
calls
2.52M
puts
Total value of holdings
$8.99B
$122M
calls
$51.1M
puts
Market Cap
$14.3B
704,382,976
Shares Out.
Institutional ownership
62.89%
# of Institutions
377
We take great care to ensure that the data presented and summarized in this overview for Roivant Sciences Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ROIV
View all-
Morgan Stanley New York, NY44.3MShares$899 Million0.04% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X040.3MShares$818 Million4.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA38.8MShares$787 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$718 Million0.01% of portfolio
-
Qvt Financial LP New York, NY29.4MShares$596 Million36.4% of portfolio
-
Viking Global Investors LP23.6MShares$479 Million1.01% of portfolio
-
Rubric Capital Management LP New York, NY20MShares$406 Million4.97% of portfolio
-
State Street Corp Boston, MA18.7MShares$379 Million0.01% of portfolio
-
Patient Square Capital LP Menlo Park, CA12.5MShares$253 Million50.51% of portfolio
-
Two Seas Capital LP Rye, NY11.8MShares$238 Million3.53% of portfolio
Latest Institutional Activity in ROIV
Top Purchases
Top Sells
About ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Insider Transactions at ROIV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2025
|
Mayukh Sukhatme President & CIO |
SELL
Other acquisition or disposition
|
Direct |
1,430,882
-7.06%
|
$30,048,522
$21.71 P/Share
|
|
Dec 31
2025
|
Mayukh Sukhatme President & CIO |
SELL
Open market or private sale
|
Direct |
1,018,995
-4.79%
|
$21,398,895
$21.71 P/Share
|
|
Dec 31
2025
|
Mayukh Sukhatme President & CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,449,877
+10.32%
|
$29,398,524
$12.68 P/Share
|
|
Dec 29
2025
|
Mayukh Sukhatme President & CIO |
SELL
Other acquisition or disposition
|
Direct |
436,485
-2.26%
|
$9,166,185
$21.74 P/Share
|
|
Dec 29
2025
|
Mayukh Sukhatme President & CIO |
SELL
Open market or private sale
|
Direct |
311,873
-1.59%
|
$6,549,333
$21.74 P/Share
|
|
Dec 29
2025
|
Mayukh Sukhatme President & CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
748,358
+3.68%
|
$8,980,296
$12.68 P/Share
|
|
Dec 24
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
75,000
-4.34%
|
$1,650,000
$22.53 P/Share
|
|
Dec 24
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
117,848
+6.38%
|
$353,544
$3.85 P/Share
|
|
Dec 24
2025
|
Frank Torti President and Vant Chair |
SELL
Bona fide gift
|
Direct |
110,489
-0.8%
|
-
|
|
Dec 24
2025
|
Frank Torti President and Vant Chair |
SELL
Other acquisition or disposition
|
Direct |
64,891
-0.47%
|
$1,427,602
$22.47 P/Share
|
|
Dec 23
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
200,000
-11.04%
|
$4,400,000
$22.45 P/Share
|
|
Dec 23
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
313,841
+14.76%
|
$941,523
$3.85 P/Share
|
|
Dec 23
2025
|
Richard Pulik CFO |
SELL
Open market or private sale
|
Direct |
406,731
-39.12%
|
$8,948,082
$22.42 P/Share
|
|
Dec 23
2025
|
Richard Pulik CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
260,000
+28.69%
|
$780,000
$3.85 P/Share
|
|
Dec 23
2025
|
Frank Torti President and Vant Chair |
BUY
Grant, award, or other acquisition
|
Direct |
175,380
+1.25%
|
$3,858,360
$22.45 P/Share
|
|
Dec 20
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,129
-0.55%
|
$46,838
$22.41 P/Share
|
|
Dec 17
2025
|
Mayukh Sukhatme President & CIO |
SELL
Other acquisition or disposition
|
Direct |
32,682
-0.17%
|
$751,686
$23.09 P/Share
|
|
Dec 17
2025
|
Mayukh Sukhatme President & CIO |
SELL
Open market or private sale
|
Direct |
26,831
-0.14%
|
$617,113
$23.09 P/Share
|
|
Dec 17
2025
|
Mayukh Sukhatme President & CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
59,513
+0.31%
|
$714,156
$12.68 P/Share
|
|
Dec 17
2025
|
Keith S Manchester |
SELL
Open market or private sale
|
Indirect |
777,332
-1.53%
|
$17,878,636
$23.08 P/Share
|
Last 12 Months Summary
Buy / Acquisition
50.5M
Shares
From
18
Insiders
| Grant, award, or other acquisition | 14.5M shares |
|---|---|
| Exercise of conversion of derivative security | 22.7M shares |
| Open market or private purchase | 3.32K shares |
| Bona fide gift | 13.4M shares |
Sell / Disposition
142M
Shares
From
29
Insiders
| Payment of exercise price or tax liability | 184K shares |
|---|---|
| Other acquisition or disposition | 99.3M shares |
| Open market or private sale | 29.2M shares |
| Bona fide gift | 13.5M shares |